Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts.
Dabas R, Lee R, Servito MT, Dharmani-Khan P, Modi M, van Slyke T, Luider J, Durand C, Larratt L, Brandwein J, Morris D, Daly A, Khan FM, Storek J. Dabas R, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2016 May;22(5):815-24. doi: 10.1016/j.bbmt.2016.01.002. Epub 2016 Jan 9. Biol Blood Marrow Transplant. 2016. PMID: 26779931 Free article. Clinical Trial.
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Stewart DA. Russell JA, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2007 Jul;13(7):814-21. doi: 10.1016/j.bbmt.2007.03.003. Epub 2007 Apr 23. Biol Blood Marrow Transplant. 2007. PMID: 17580259 Free article.
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, Savoie ML, Bahlis NJ, Brown C, Storek J, Andersson BS, Russell JA. Geddes M, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2008 Feb;14(2):220-8. doi: 10.1016/j.bbmt.2007.10.028. Biol Blood Marrow Transplant. 2008. PMID: 18215782 Free article. Clinical Trial.
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA. Russell JA, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2008 Aug;14(8):888-95. doi: 10.1016/j.bbmt.2008.05.010. Biol Blood Marrow Transplant. 2008. PMID: 18640572 Free article. Clinical Trial.
Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research.
Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, Pollack MS, Storek J, Thompson JC, Tiberghien P, Young JA, Ribaud P, Horowitz MM, Keating A. Gupta V, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2009 Jul;15(7):864-71. doi: 10.1016/j.bbmt.2009.03.023. Biol Blood Marrow Transplant. 2009. PMID: 19539219 Free PMC article. Clinical Trial.
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA. Russell JA, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2010 Apr;16(4):509-14. doi: 10.1016/j.bbmt.2009.11.017. Epub 2009 Dec 3. Biol Blood Marrow Transplant. 2010. PMID: 19948235 Free article.
High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder.
Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. Podgorny PJ, et al. Among authors: storek j. Biol Blood Marrow Transplant. 2010 Jul;16(7):915-26. doi: 10.1016/j.bbmt.2010.02.027. Epub 2010 Mar 11. Biol Blood Marrow Transplant. 2010. PMID: 20226870 Free article.
193 results